Ashling Mulvaney has been in the pharmaceutical industry for 20 years, and with AstraZeneca since 2008, in a range of access-focused roles across therapy areas including cardiovascular, diabetes and respiratory. Ashling led the Global pricing and market access teams for the Cardiovascular Renal Metabolism (CVRM) portfolio and was the reimbursement expert for the acquisition of the diabetes portfolio from BristolMyers Squibb (BMS). In 2016, Ashling took on leadership of AstraZeneca’s flagship Healthy Heart Africa (HHA) programme, active since 2014 tackling hypertension and cardiovascular disease across East and West Africa, as well as India. In her current role as VP Sustainability, Access to Healthcare, & Healthy Heart Africa, Ashling leads one of the three priority pillars of AstraZeneca’s sustainability strategy, working towards a future where all people have access to sustainable healthcare solutions for life-changing treatment and prevention. She focuses on addressing the burden of non-communicable diseases in emerging economies, by working with stakeholders and in public-private partnerships to promote disease prevention, remove barriers to access, and strengthen health systems in support of local communities for greatest impact. AstraZeneca’s access programmes had reached more than 31m people and trained more than 199,000 healthcare workers and others by the end of 2021. In April 2020, Ashling took on the role of Co-Chair of Private Sector Roundtable (PSRT), part of the Global Health Security Agenda (GHSA), which highlights the critical role that the private sector plays in responding to global health challenges and emergencies. In January 2022, Ashling became Chair of the US Agency for International Development (USAID) funded Strategies to Prevent Spillover (STOP Spillover) External Advisory Board. STOP Spillover works with in-country stakeholders to understand and address the threats posed by zoonotic viral diseases and reduce the risk of viral spillover and spread.